Ann: R327 Efficacy against WHO Priority Pathogen Acinetobacter B, page-12

First 12 Last

Share
Profile

Follow
rl

87 Posts.

13

09/07/24

21:47

Post #: 74680005
Share

Originally posted by zecs: ↑

There has been zero explanation about why they couldn't recruit for the Burns or the DFI trials. On the contrary, they continue to refer to the burns trial as "successful" or "complete", rather than the actual: "stopped early due to participant recruitment difficulties".

And the problem with those random photos of patients is that they are not science. They are purely designed to impress naive retail investors, thinking that they are meaningful. They are not controlled, we have no idea if RCE pixie juice was responsible for any improvement, or how the product was used, what other therapies the patient was taking, how much placebo was involved, how many patients accessed under the scheme that we didn't hear about.

If the product is so effective, why do they struggle to recruit their trials?

Expand

Thank you for the answer... I think you wrote in an earlier post that you own RCE shares. The directors own about 10 million between them plus options..
Do you think this is a genuine and potentially game changing product? If so what's your best guess as to the reason for the lack of trials?

RCE Price at posting: 46.5¢ Sentiment: Hold Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

ASX Market Open: Hopes turn on Israel-Iran attacks barely rattling crude price | June 17, 2025

RC1

Redcastle teams up with Terra Mining to get revenue flowing at Redcastle Reef, Queen Alexandra projects

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

ASM

'Encouraging' signs as ASM puts cash-saving options to test at Dubbo drill site

ASX Market Close: Index treads water as Energy stocks surge | June 16, 2025

First 12 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 30.5¢		Change 0.000(0.00%)		Mkt cap ! $87.95M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
5	31155	30.0¢

Sellers (Offers)

Price($)	Vol.	No.
30.5¢	21198	4

View Market Depth

No.	Vol.	Price($)
5	31155	0.300
1	523	0.295
7	35706	0.290
2	135000	0.285
8	133306	0.280

Price($)	Vol.	No.
0.305	17280	2
0.310	2203	1
0.320	523	1
0.325	523	1
0.330	25000	1

Last trade - 10.18am 17/06/2025 (20 minute delay)

RCE (ASX) Chart

Ann: R327 Efficacy against WHO Priority Pathogen Acinetobacter B, page-12

ASX Market Open: Hopes turn on Israel-Iran attacks barely rattling crude price | June 17, 2025

Redcastle teams up with Terra Mining to get revenue flowing at Redcastle Reef, Queen Alexandra projects

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

'Encouraging' signs as ASM puts cash-saving options to test at Dubbo drill site

ASX Market Close: Index treads water as Energy stocks surge | June 16, 2025

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: R327 Efficacy against WHO Priority Pathogen Acinetobacter B, page-12

Top Stories

ASX Market Open: Hopes turn on Israel-Iran attacks barely rattling crude price | June 17, 2025

Redcastle teams up with Terra Mining to get revenue flowing at Redcastle Reef, Queen Alexandra projects

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

'Encouraging' signs as ASM puts cash-saving options to test at Dubbo drill site

ASX Market Close: Index treads water as Energy stocks surge | June 16, 2025

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News